EDIT - Why Shares of Bluebird Bio CRISPR Therapeutics and Editas Medicine Soared This Week
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by 17% over the holiday-shortened week as of Thursday's closing bell, according to data provided by S&P Global Market Intelligence .
What's more, shares of CRISPR Therapeutics (NASDAQ: CRSP) have gained 22.6% over the same period, and fellow gene editor Editas Medicine (NASDAQ: EDIT) also saw its equity rise in price by a healthy 20.7% this week. By contrast, Bluebird and Editas shares both fell by over 50% over the first six months of 2022, while CRISPR's stock price stumbled by a noteworthy 20% during the first half of the year.
Image Source: Getty Images.
For further details see:
Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This Week